Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy

Solid Neoplasm Clinical Trial

Official title: Accelerometry to Optimize and Monitor Human Performance in Cancer Chemotherapy Outpatients

Status Active, not recruiting

Clinical Trial Summary

This clinical trial studies movement tracking devices in optimizing and monitoring physical activity in patients with solid tumors undergoing chemotherapy in a health care facility during the day without spending the night. Movement tracking devices, such as Microsoft Kinect 2 and Microsoft Band 2, may help doctors learn about the health of cancer patients.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the feasibility of monitoring cancer patients using wrist-worn activity monitors and movement trackers.

SECONDARY OBJECTIVES:

I. To evaluate the association between activity and patient reported fatigue. II. To evaluate the association between movement and incidents of health care interventions (hospitalizations, physical visits, intravenous hydration, etc.)

TERTIARY OBJECTIVES:

I. To compare physician and patient assessed Eastern Cooperative Oncology Group (ECOG) and Karnofsky performance status scores with the data obtained from movement trackers.

OUTLINE:

Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based patient reported outcome (PRO) questionnaire, and weigh themselves daily for 60 days.

After completion of study, patients are followed up at 90 days. ;

Related Conditions & MeSH terms

• Solid Neoplasm

• NCT number: NCT03098277
• Study type: Interventional
• Source: University of Southern California
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 6, 2016
• Completion date: December 6, 2024